Achieve Life Sciences Inc (ACHV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$7.54-3.83%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Achieve Life Sciences aims to raise $354 million through private placement. The company beat Q1 2026 EPS expectations, showing progress managing losses. New board members bring fresh oversight. Stable market conditions support the turnaround story.
The company remains loss-making with negative EPS guidance near -1.25 in 2026. Key executives have departed, including the Chief Commercial Officer and President. Revenue remains uncertain with wide guidance range. Funding risks and execution challenges persist.
No clear market consensus or fair value is available. The stock likely prices in ongoing losses and execution risk. Our view differs by emphasizing the importance of successful funding and loss management for recovery.
Breaks if: Any additional departure of C-suite or President within next 4 quarters
Breaks if: EPS falls below -1.25 USD per share in 2026-Q4
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis is cautious due to recent earnings misses and increasing net losses, while management is focused on securing funding and advancing manufacturing.
The market seems to have low expectations for ACHV, as indicated by its recent performance and the lack of fragility in its valuation. There is an expectation of continued losses, but the sector's overall momentum may provide some support.
Fundamentals are likely to remain weak in the near term, with increasing net income losses and a high probability of missing earnings expectations. Management is on track with funding efforts, but recent changes indicate a mixed outlook.
The future performance of ACHV hinges on several factors, including the potential for guidance cuts and the impact of macroeconomic conditions like job reports. Additionally, the performance of sector leaders could influence ACHV's trajectory.
The most important moves since the prior daily snapshot.
Company momentum fell by 15.8 points (from -42.9 to -58.7).
No, our read on the company is unchanged. The recent financial performance remains weak. The sector backdrop is supportive, which helps maintain the current outlook. There are no new threats or supports impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: gross proceeds fall below $180 million by 2026-Q1
Complete and utilize private placement financing to fund Phase 3 trial, commercialization, and working capital.
Stated as a priority in 2 of last 2 quarters. Management closed a private placement of up to $354 million including $180 million upfront and $174 million from milestone warrants in 2026-Q1. This funding is intended to support the Phase 3 trial and commercialization. The trajectory is delivering as the financing closed and proceeds are available.
“Closed a private placement of up to $354 million, including $180 million upfront and up to $174 million from milestone-based warrants.”
“Entered into a securities purchase agreement for a private placement of gross proceeds up to approximately $354 million.”
In the next 1 to 3 years, ACHV's prospects will depend on its ability to manage losses and navigate a challenging environment. Not investment advice.